The Israeli Company, Vaxil BioTherapeutics Ltd, has announced that its lead drug candidate, ImMucin, has been granted orphan drug designation by the European Medicines Agency (EMA). ImMucin is a 21mer synthetic vaccine composed of the entire signal peptide domain of MUC1, a protein that is highly expressed on the surface of myeloma cells. It is designed to stimulate an immune response against MUC1, thereby allowing the patient’s own immune system to recognise and destroy myeloma cells. The new orphan drug status will help support further development of ImMucin as a treatment for myeloma.


Read full article